If you are weighing up whether stepping up to Wegovy 7.2 mg is worth it, the honest answer depends on numbers most comparisons gloss over: not just an average weight loss figure, but how many people actually reached meaningful thresholds, and what you trade for that extra effect. Here is what the trial behind this dose actually found.
Table of Contents
1. What Was The STEP UP Trial, Exactly?
2. How Does 7.2 mg Compare With 2.4 mg And Placebo?
3. How Many People Reached 10%, 15%, 20% And 25% Weight Loss?
4. Why Do Individual Results Vary So Much?
5. Are Side Effects Worse On 7.2 mg?
6. What About Less Common Or Serious Risks?
7. Is Stepping Up Right For You?
8.1. How Much More Weight Can You Lose With Wegovy 7.2 mg Compared To 2.4 mg?
8.2. Who Is Eligible For Wegovy 7.2 mg, And When Can You Increase The Dose?
8.3. How Should Clinicians Interpret Wegovy Clinical Trial Results For Patient Counselling?
8.4. How Long Does Wegovy 7.2 mg Take To Start Working?
8.5. Does Wegovy 7.2 mg Cause More Side Effects Than The 2.4 mg Dose?
8.6. What Happens If You Stop Taking Wegovy 7.2 mg? Will The Weight Come Back?
What Was The STEP UP Trial, Exactly?
The STEP UP trial followed 1,407 adults with obesity (BMI 30 or above) who did not have type 2 diabetes. It was a 72-week, randomised, double-blind trial comparing Wegovy 7.2 mg with the standard 2.4 mg dose and placebo.
Participants were recruited from 95 hospitals, specialist clinics and medical centres across 11 countries. They were randomly assigned to one of the three groups in a 5:1:1 ratio, with all groups also receiving lifestyle support. A separate companion study, STEP UP T2D, looked at the same dose comparison in 512 adults with obesity and type 2 diabetes.
How Does 7.2 mg Compare With 2.4 mg And Placebo?
Clearly ahead of both on average weight loss, though you will see two slightly different figures depending on how adherence is counted. The published results reported 18.7% average weight loss on 7.2 mg, regardless of how consistently people took it, against 15.6% on 2.4 mg and 3.9% on placebo. Counting only those who took treatment as intended, the figures rise to 20.7%, 17.5% and 2.4% respectively.
| Wegovy 7.2 mg | Wegovy 2.4 mg | Placebo | |
|---|---|---|---|
| Average weight loss (regardless of adherence) | 18.7% | 15.6% | 3.9% |
| Average weight loss (full adherence) | 20.7% | 17.5% | 2.4% |
How Many People Reached 10%, 15%, 20% And 25% Weight Loss?
The STEP UP trial found that a higher proportion of participants receiving semaglutide 7.2 mg achieved weight loss of 10%, 15%, 20% and 25% or more by week 72 compared with those receiving 2.4 mg or placebo.
| Threshold (treatment policy estimand, regardless of adherence) | 7.2 mg | 2.4 mg | Placebo |
|---|---|---|---|
| 10% or more | 82.4% | 75.1% | 20.5% |
| 15% or more | 66.5% | 54.5% | 7.6% |
| 20% or more | 47.7% | 33.3% | 2.9% |
| 25% or more | 31.2% | 15.3% | 0% |
Around one in three participants receiving semaglutide 7.2 mg lost 25% or more of their body weight, compared with around one in six receiving 2.4 mg. No participants in the placebo group reached this threshold.
All figures represent the proportion of participants achieving each weight-loss threshold from baseline to week 72.
Why Do Individual Results Vary So Much?
Because a trial average describes the whole group, not any one person's outcome. These figures span people who lost very little and people who lost substantially more than the average, and factors such as starting weight, how closely the lifestyle changes were followed, and individual biological response all affect where someone lands. These are trial results, not a prediction of your own outcome, and no reputable source can promise you a specific figure.
Are Side Effects Worse On 7.2 mg?
Some side effects were more common with the higher dose, particularly gastrointestinal problems and dysaesthesia. Gastrointestinal adverse events were the most frequently reported, affecting 70.8% of participants taking 7.2 mg. This compared with 61.2% on 2.4 mg and 42.8% on placebo. Despite this difference, only 3.3% of participants in the 7.2 mg group stopped treatment because of these effects.
Another finding worth paying attention to was dysaesthesia. This describes unusual or uncomfortable sensations, such as tingling, burning or changes in skin sensitivity. It was reported by 22.9% of participants taking 7.2 mg, compared with 6.0% on 2.4 mg and 0.5% on placebo.
That is quite a difference between the two doses. It suggests that the higher dose may bring a greater likelihood of sensory disturbances alongside the more familiar gastrointestinal side effects. It is something I would want patients to be aware of before discussing a dose increase with their prescriber.
What About Less Common Or Serious Risks?
Serious adverse events were reported in a similar range across all three groups, 6.8% on 7.2 mg, 10.9% on 2.4 mg and 5.5% on placebo, so this was not a simple dose dependent pattern in this trial. As with any GLP-1 medicine, pancreatitis, gallbladder problems and, very rarely, diabetic eye complications remain possibilities worth knowing the warning signs for. If you notice anything that concerns you, tell your prescriber, and you can also report a suspected side effect yourself through the MHRA's Yellow Card scheme, regardless of whether your prescriber has already done so.
Is Stepping Up Right For You?
There is no single answer that applies to everyone. Your prescriber will look at how much weight you have lost on 2.4 mg, how well you have tolerated the treatment and whether the potential additional benefit of 7.2 mg outweighs the higher likelihood of certain side effects.
A higher dose does not automatically mean a better choice for every patient. Your prescriber will review your progress and medical history before deciding whether an increase is appropriate.
If you are considering moving up to 7.2 mg, we can help you understand whether the higher dose is suitable for you, taking your progress, treatment experience and individual needs into account. Start your consultation with Pharmacy Planet to discuss your options and decide on the next step with professional guidance.
Frequently Asked Questions
How Much More Weight Can You Lose With Wegovy 7.2 mg Compared To 2.4 mg?
Trial averages were around 3 percentage points higher on 7.2 mg (18.7% versus 15.6%, or 20.7% versus 17.5% with full adherence), though individual results vary considerably.
Who Is Eligible For Wegovy 7.2 mg, And When Can You Increase The Dose?
Adults with obesity (BMI 30 or above) who have completed the standard titration and spent a minimum of 4 weeks on 2.4 mg, subject to your prescriber's assessment. Our dedicated eligibility guide covers this in full.
How Should Clinicians Interpret Wegovy Clinical Trial Results For Patient Counselling?
Trial averages and threshold data describe group outcomes under trial conditions, not individual guarantees, and should be presented alongside the corresponding side effect rates so patients can weigh both together, consistent with shared decision making.
How Long Does Wegovy 7.2 mg Take To Start Working?
The trial measured outcomes at 72 weeks, and the dose itself is only reached after completing the full titration schedule, so meaningful results build gradually over months rather than appearing quickly.
Does Wegovy 7.2 mg Cause More Side Effects Than The 2.4 mg Dose?
Gastrointestinal side effects were somewhat more common, and dysaesthesia was notably more frequent (22.9% against 6.0%). Serious adverse events overall were not clearly higher on 7.2 mg than on 2.4 mg in this trial.
What Happens If You Stop Taking Wegovy 7.2 mg? Will The Weight Come Back?
Weight regain after stopping is well documented with GLP-1 medicines generally, since the underlying appetite regulation effect does not persist once treatment ends. This is a conversation to have with your prescriber rather than something to decide alone.
Is Wegovy 7.2 mg Safe For Long Term Use?
The published trial followed people for 72 weeks, so reliable safety data beyond that period is more limited, and ongoing monitoring by your prescriber matters for as long as you continue treatment.
This article is for general information and is not medical advice. Wegovy is a prescription only medicine and is supplied only after a clinical assessment. Trial results are averages and do not predict any individual outcome. Report any suspected side effect through the MHRA's Yellow Card scheme or to your prescriber.
Sources Referenced
- Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, Quiroga M, Rosenstock J, Garvey WT; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949 to 963. The primary source for the trial design, the weight loss figures under both estimands, the weight loss threshold table, and the gastrointestinal, dysaesthesia and serious adverse event rates.
- Efficacy and safety of semaglutide 7.2 mg in obesity: STEP UP trial. Obesity Abstracts (2025) 5 P3. DOI: 10.1530/obabs.05.P3. The source for the weight loss threshold table, confirmed as the treatment policy estimand (regardless of adherence).
- Lingvay I, Bergenheim SJ, Buse JB, et al; STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935 to 948.
- MHRA, Yellow Card scheme


